Pretreatment tumor volume estimation based on total serum psa in patients with localized prostate cancer

OBJECTIVES: To establish a formula that estimates tumor volume in localized prostate cancer based on serum prostate specific antigen levels. One of the main prognostic variables in localized prostate cancer is tumor volume, which can be precisely defined only after prostate extirpation. The present study defines a simple method that allows for estimation of tumor volume before treatment, which can help to establish a better therapeutic strategy for each patient. METHODS: From 1997 to 2002, 735 patients with prostate cancer of stagesT1c-T2c without any previous treatment were submitted to radical prostatectomy. Surgical specimens were evaluated by the same pathologist and the total tumor volume (in cc) and the relative tumor volume (as the percent of the total prostate volume) were determined using the grid morphometric method. Pretreatment serum prostate specific antigen was correlated with tumor volume in each patient using a linear regression model. RESULTS: There were positive correlations between the serum levels of prostate specific antigen and the total tumor volume in cc (p<0.001) and the relative tumor volume as a percentage (p<0.001). For each ng/ml unit increment of serum prostate specific antigen, there was a 0.302 cc increase in total tumor volume and a 0.7% increase in relative tumor volume. Total and percent tumor volume could be calculated, respectively, using the formulas Volume (cc) = 3.476 + 0.302 x PSA (ng/ml) and Volume (%) = 11.331 + 0.704 x prostate specific antigen (ng/ml). CONCLUSIONS: Tumor volume in patients with prostate cancer can be determined before treatment based on the serum prostate specific antigen levels.

Saved in:
Bibliographic Details
Main Authors: Kato,Raphael Barroso, Srougi,Victor, Salvadori,Fernanda Aburesi, Ayres,Pedro Paulo Marino Rodrigues, Leite,Katia Moreira, Srougi,Miguel
Format: Digital revista
Language:English
Published: Faculdade de Medicina / USP 2008
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322008000600009
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S1807-59322008000600009
record_format ojs
spelling oai:scielo:S1807-593220080006000092008-12-03Pretreatment tumor volume estimation based on total serum psa in patients with localized prostate cancerKato,Raphael BarrosoSrougi,VictorSalvadori,Fernanda AburesiAyres,Pedro Paulo Marino RodriguesLeite,Katia MoreiraSrougi,Miguel Prostate Cancer Tumor Volume Prognosis Prostate Specific Antigen Radical Prostatectomy OBJECTIVES: To establish a formula that estimates tumor volume in localized prostate cancer based on serum prostate specific antigen levels. One of the main prognostic variables in localized prostate cancer is tumor volume, which can be precisely defined only after prostate extirpation. The present study defines a simple method that allows for estimation of tumor volume before treatment, which can help to establish a better therapeutic strategy for each patient. METHODS: From 1997 to 2002, 735 patients with prostate cancer of stagesT1c-T2c without any previous treatment were submitted to radical prostatectomy. Surgical specimens were evaluated by the same pathologist and the total tumor volume (in cc) and the relative tumor volume (as the percent of the total prostate volume) were determined using the grid morphometric method. Pretreatment serum prostate specific antigen was correlated with tumor volume in each patient using a linear regression model. RESULTS: There were positive correlations between the serum levels of prostate specific antigen and the total tumor volume in cc (p<0.001) and the relative tumor volume as a percentage (p<0.001). For each ng/ml unit increment of serum prostate specific antigen, there was a 0.302 cc increase in total tumor volume and a 0.7% increase in relative tumor volume. Total and percent tumor volume could be calculated, respectively, using the formulas Volume (cc) = 3.476 + 0.302 x PSA (ng/ml) and Volume (%) = 11.331 + 0.704 x prostate specific antigen (ng/ml). CONCLUSIONS: Tumor volume in patients with prostate cancer can be determined before treatment based on the serum prostate specific antigen levels.info:eu-repo/semantics/openAccessFaculdade de Medicina / USPClinics v.63 n.6 20082008-01-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322008000600009en10.1590/S1807-59322008000600009
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Kato,Raphael Barroso
Srougi,Victor
Salvadori,Fernanda Aburesi
Ayres,Pedro Paulo Marino Rodrigues
Leite,Katia Moreira
Srougi,Miguel
spellingShingle Kato,Raphael Barroso
Srougi,Victor
Salvadori,Fernanda Aburesi
Ayres,Pedro Paulo Marino Rodrigues
Leite,Katia Moreira
Srougi,Miguel
Pretreatment tumor volume estimation based on total serum psa in patients with localized prostate cancer
author_facet Kato,Raphael Barroso
Srougi,Victor
Salvadori,Fernanda Aburesi
Ayres,Pedro Paulo Marino Rodrigues
Leite,Katia Moreira
Srougi,Miguel
author_sort Kato,Raphael Barroso
title Pretreatment tumor volume estimation based on total serum psa in patients with localized prostate cancer
title_short Pretreatment tumor volume estimation based on total serum psa in patients with localized prostate cancer
title_full Pretreatment tumor volume estimation based on total serum psa in patients with localized prostate cancer
title_fullStr Pretreatment tumor volume estimation based on total serum psa in patients with localized prostate cancer
title_full_unstemmed Pretreatment tumor volume estimation based on total serum psa in patients with localized prostate cancer
title_sort pretreatment tumor volume estimation based on total serum psa in patients with localized prostate cancer
description OBJECTIVES: To establish a formula that estimates tumor volume in localized prostate cancer based on serum prostate specific antigen levels. One of the main prognostic variables in localized prostate cancer is tumor volume, which can be precisely defined only after prostate extirpation. The present study defines a simple method that allows for estimation of tumor volume before treatment, which can help to establish a better therapeutic strategy for each patient. METHODS: From 1997 to 2002, 735 patients with prostate cancer of stagesT1c-T2c without any previous treatment were submitted to radical prostatectomy. Surgical specimens were evaluated by the same pathologist and the total tumor volume (in cc) and the relative tumor volume (as the percent of the total prostate volume) were determined using the grid morphometric method. Pretreatment serum prostate specific antigen was correlated with tumor volume in each patient using a linear regression model. RESULTS: There were positive correlations between the serum levels of prostate specific antigen and the total tumor volume in cc (p<0.001) and the relative tumor volume as a percentage (p<0.001). For each ng/ml unit increment of serum prostate specific antigen, there was a 0.302 cc increase in total tumor volume and a 0.7% increase in relative tumor volume. Total and percent tumor volume could be calculated, respectively, using the formulas Volume (cc) = 3.476 + 0.302 x PSA (ng/ml) and Volume (%) = 11.331 + 0.704 x prostate specific antigen (ng/ml). CONCLUSIONS: Tumor volume in patients with prostate cancer can be determined before treatment based on the serum prostate specific antigen levels.
publisher Faculdade de Medicina / USP
publishDate 2008
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322008000600009
work_keys_str_mv AT katoraphaelbarroso pretreatmenttumorvolumeestimationbasedontotalserumpsainpatientswithlocalizedprostatecancer
AT srougivictor pretreatmenttumorvolumeestimationbasedontotalserumpsainpatientswithlocalizedprostatecancer
AT salvadorifernandaaburesi pretreatmenttumorvolumeestimationbasedontotalserumpsainpatientswithlocalizedprostatecancer
AT ayrespedropaulomarinorodrigues pretreatmenttumorvolumeestimationbasedontotalserumpsainpatientswithlocalizedprostatecancer
AT leitekatiamoreira pretreatmenttumorvolumeestimationbasedontotalserumpsainpatientswithlocalizedprostatecancer
AT srougimiguel pretreatmenttumorvolumeestimationbasedontotalserumpsainpatientswithlocalizedprostatecancer
_version_ 1756432030126571520